Orchid Jahanshahi, MBA’s Post

Good morning LinkedIn!!! :) Register today for the upcoming Ontario Pharmaceutical Marketing Association March vitual event!! Join us as Christina Crowe provides her invaluable insights on this important topic!! Check out all the details below, and click on the link to register!! See you there!! :) #opma #learningtogether #neurodiversity #networking

Good morning LinkedIn!!! :) We are 2 weeks away from this important Ontario Pharmaceutical Marketing Association virtual event!! Thank you, Kristina Harrison, for joining our expert panel! We look forward to your insights, your experiences, and your guidance as we navigate this relevant and game-changing topic!! Check out all the details below!! 👇🏻 Register today!! Thanks to my network for sharing!! :) #learningtogether #neurodiversity #leadershipgoals #networking #opma

Check this program out Pharma peeps! Having perspective on Neurodiversity is more than a good thing for High-Performing Pharma teams and in this ever changing world of Pharma sales and sales in general for that matter!

Title: Developing a Tactical Plan for Key Stakeholder Identification & Engagement: The “Art” behind the Science Successfully identifying and engaging key stakeholders is pivotal for promoting awareness, advocacy, and adoption of innovative therapies in the biotech and pharmaceutical industry. Developing a tactical plan involves conducting a comprehensive landscape analysis to pinpoint influencers and understand their interests. Strategic partnerships are then established with Key Opinion Leaders (KOLs), patient advocacy groups, professional societies, and healthcare centers to foster collaboration and alignment. Tailored engagement strategies are crafted for each stakeholder group, focusing on scientific exchange, educational initiatives, and collaborative research projects. Building meaningful and sustainable relationships through ongoing communication and responsiveness is crucial for long-term success. Leveraging technology and digital platforms enhances outreach and engagement, maximizing impact in a rapidly evolving healthcare landscape. Overall, a strategic approach that leverages insights, relationships, and resources is essential for effective stakeholder engagement and advancing scientific innovation to improve patient outcomes. Read the full article @ https://lnkd.in/effhmq5H

What Doctors Want in 2024 Out today the second in our series of insights from the 2024 So What? Research Survey of Australian Doctors, looks at: - Top 7 things doctors want more of from pharma - What's going well and what can be improved - Opportunities to do better without reinventing the wheel - How to get more engagement with HCPs Read here: https://lnkd.in/g5JJrhz7 #marketresearch #healthcareresearch

🚀 Calling all innovators! The InnoStars Connect programme is here to revolutionise healthcare innovation across Central Eastern and Southern Europe, and we want your groundbreaking ideas to be part of it! This cross-border collaborative initiative brings together industry leaders, start-ups, SMEs, universities, research institutions, and hospitals to drive meaningful change in healthcare. 🌟 What's in it for you? 🤝 Strategic Pharma Partnerships: Join forces with front-runner pharmaceutical companies Chiesi Group and SYNLAB Italia for unparalleled collaboration and growth opportunities. 💡 Cutting-Edge Challenges: Tackle pressing healthcare issues in early diagnostics, patient care, drug delivery, and rare disease therapy, paving the way for innovative solutions. 🎓 Validating and scaling solutions: Through tailored bootcamps online and offline sessions, in close collaboration with industry experts 💰 Funding Opportunities: Secure potential funding and strategic alliances to turn your innovative ideas into impactful solutions. 🌐 Community Membership: Expand your social capital and tap into EIT Health's extensive network and services. Learn more and apply by June 30: https://lnkd.in/dyZ2xfyj #InnoStarsConnect #CrossBorderCollaboration #OpenInnovation

Zuellig Pharma was honoured to be a part of the 2024 Annual J.P. Morgan Healthcare Conference in San Francisco last week, the largest and most informative healthcare investment symposium in the industry connecting over 8,000 global industry leaders, executives and investors. With an optimistic outlook for 2024, conversations centred around the future of healthcare fuelled by an improving global economy, rising merger and acquisition activity, biopharmas’ increasing focus on key therapeutic areas such as obesity, a growing interest in China and the FDA’s focus on artificial intelligence and data and enterprise transformation.   Our Group CEO John A. Graham shared key insights on the growing Southeast and North Asia region, which represents the world’s third-largest market with a population of 1 billion people, before diving into how Zuellig Pharma connects biopharma companies, healthcare professionals, patients and consumers across the healthcare value chain in the region. In particular, he shed light on how Zuellig Pharma builds strategic commercial partnerships to support companies in attaining market leadership in key therapeutic areas, and leverages technology for our innovative market-leading digital tools and support programmes.   As a leading integrated healthcare solutions company, Zuellig Pharma powers the healthcare ecosystem through our wide range of solutions, from commercialisation and market expansion, distribution, clinical trials and sourcing to contract manufacturing. We look forward to deepening existing strategic partnerships and striking up new collaborations with multinational healthcare leaders in 2024, as we remain focused on our mission of making healthcare more accessible in Asia.   #JPMHC24 #HealthcareTrends #MakingHealthcareMoreAccessible 

After a year of conversations and filming, I’m proud to launch our Outside In(novation) series, by far one of the most fascinating projects I’ve worked on during my tenure at Novartis. Made in collaboration with leaders from the patient; founder; investment; academic; pharma; and policy communities, we’ll be posting highlights from some candid conversations around what exactly patient-centricity means for healthcare innovation…. and where we still need to do the hard yards to ensure that new innovations actually reach and impact the communities that they intend to serve.   We aimed to go far beyond the buzz words, and to ask some thornier questions. These include: 👉 How are patient communities directly driving investment in modern healthcare? 👉   How does proper community engagement track to building out a value proposition for a new innovation? 👉 How does one maintain patient-centricity when building out tools for a healthcare system, which may have population-level incentives?  👉 ⭐ And a super crucial one: what can collaborators do differently (and better) when engaging communities?   Those we interviewed were optimistic on a shift from people asking *why* we need to build innovation from the outside in, but rather *how best* to do it.  We at Novartis agree: we remain committed to ensuring that our research and development efforts are built hand-in-hand with the patient community from day one, and that these collaborations extend to shared advocacy for healthcare and access policies that more clearly serve patients. More importantly, we also understand that partnering with communities is an iterative process: innovators of all sizes must always be in “learning mode” as they jointly navigate a path to cutting-edge innovations.  Bottom line: it’s clear how far we’ve already come together, and how much further we'll get together.   A huge thanks to everyone that helped bring this series to life, from those we interviewed to the many creatives that lent their talents to the myriad locations that let us set up and film.   Follow this space for more, starting next week with Orla Galvin BSc PhD Galvan from EFNA! Julia Hawkins|Julia Fan Li|Srin Madipalli|Matthieu Vallin|Wim Van Hecke|Dirk Smeets|Tracey Dawson, PhD|Robert Baloh|Lucy Jung|Sarah Ranchev-Hale|Paola Barbarino|chas bountra|Stephanie Campbell, PhD|Lucy Jones|Justus Bruns|Jack Belisle|Annie Mullee|Alexandra Kubara|European Brain Council|Stephanie Kramer|Harris Eyre MD PhD|Paweł Świeboda|Norman Putzki, MD|Nicole Yurgin|Beth Wolff|Ben Mumby-Croft|Maureen Barry|Anne Kim|Imperial Enterprise Lab   #outsideinnovation #pharma #healthcare #patient #venture #vc #research #founders #healthpolicy #researchanddevelopment #biotech #HealthcareInnovation #PatientCentered #PharmaceuticalIndustry #HealthTech #Innovation #HealthcareTransformations #PharmaInnovation #HealthcareSeries #PatientJourney #HealthcareLeadership #HealthcareTechnology #PatientEmpowerment

I recently had the privilege of interviewing Amy West, Head of US Digital Health & Innovation Strategy at Novo Nordisk, for HealthIMPACT Live's Digital Health Talks podcast. Amy opened my eyes to the crucial, often underappreciated role that pharmaceutical companies play in our healthcare ecosystem. She shared how Novo Nordisk harnesses data and technology to enhance healthcare access for underserved communities. Key insights from our chat: * Innovative use of digital health tech to close care gaps * Leveraging data to amplify patient voices * Implementing ethical, inclusive digital transformation strategies It's clear that pharma's impact extends far beyond medication - they're driving patient-centered innovation and promoting health equity. I'm impressed by Amy and Novo Nordisk's commitment to transformative healthcare solutions. This conversation reinforced the importance of cross-industry collaboration in achieving better health outcomes for all Listen here: https://lnkd.in/eJGUFMpP What are your thoughts on pharma's evolving role in digital health transformation? Let's continue this important dialogue! #DigitalHealth #HealthcareInnovation #Pharma #HealthEquity #HealthIMPACT

𝗦𝗲𝗻𝗶𝗼𝗿 𝗧𝗮𝗹𝗲𝗻𝘁 𝗦𝗵𝗶𝗳𝘁 𝗤𝟮 𝟮𝟬𝟮𝟰 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 In Q2 2024, there have been notable senior-level changes across the Real World Evidence, Digital Health, Consulting, and CDMO sectors. These shifts reflect the industry's ongoing evolution and the increasing demand for leaders with expertise in business transformation, strategic change, and entrepreneurial drive. In the Real World Evidence sector, new senior leaders have been appointed to spearhead efforts in leveraging real-world data for enhanced clinical and commercial insights. These changes aim to strengthen capabilities in generating robust evidence to support regulatory submissions and market access strategies in a highly competitive field, marked by fierce competition from both large corporations and smaller enterprises. 𝗨𝗦𝗔 Kyle Armbrester - CEO at Datavant Brett Kleger - CEO at Inspire Rachael Thomas Higgins - CCO at PicnicHealth Jade Cusick - CCO at Ontada Ben Stormer - CCO at Annexus Health Ryan Sloan - CGO at Galileo Jennifer M. - CGO at Lightship Lindsay Daniel - CHRO at YPrime Joshua Max Davis - SVP Commercial Operations at Ada Health Amy Eaves - BU Head Healthcare & Life Sciences at Synoptek 𝗘𝘂𝗿𝗼𝗽𝗲 Marc Funk - CEO at MARBIO Abdelaziz Toumi, PhD, MBA - CEO at Lupin Jonathan Burr - CCO at Cytel Martin Keil - VP & GM at Revvity Roberto Ascione - President at EVERSANA Pamela V. - VP HEOR, Value & Evidence at EVERSANA Jean-Christophe Massot - VP Information & Communications ProductLife Group Frédéric GAUSSENS - VP Europe & APAC PharmaLex We are excited to see how Q3 unfolds with any future senior talent shifts. If you are seeking senior-level opportunities or looking to attract senior talent, please contact our executive search team at Luminary Group. Stay tuned for the next series! #realworldevidence #rwe #rwd #regulatoryaffairs #cdmo #pharmaceutical #biotechnology